Sugi Predict

Sugi Predict / Compounds / SCHEMBL141523

SCHEMBL141523

SCHEMBL141523

COC(=O)c1cc(-c2ccc(OC)c(F)c2)nc2c3ccc(Cl)cc3n(Cc3ccc(OC)cc3)c12

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PLA2G2A P14555 4/20 0.47
▸ P2RX3 P56373 4/20 0.40
▸ CCR2 P41597 1/20 0.40
▸ JAK2 O60674 2/20 0.39
▸ KDM4E B2RXH2 1/20 0.38
▸ DHODH Q02127 1/20 0.38
▸ MAPT P10636 2/20 0.38
▸ MEN1 O00255 2/20 0.38
▸ KMT2A Q03164 2/20 0.38
▸ TP53 P04637 2/20 0.38
▸ THRB P10828 1/20 0.38
▸ RGS12 O14924 1/20 0.38
▸ ALDH1A1 P00352 1/20 0.38
▸ LMNA P02545 1/20 0.38
▸ CYP1A2 P05177 1/20 0.38
▸ CYP3A4 P08684 1/20 0.38
▸ CYP2C9 P11712 1/20 0.38
▸ PKM P14618 1/20 0.38
▸ TSHR P16473 1/20 0.38
▸ NFKB1 P19838 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL110326 0.94 P2RX3 (0.40) PLA2G2AP2RX3JAK2KDM4EDHODH
SCHEMBL143205 0.86 PLA2G2A (0.49) PLA2G2ACCR2KDM4EMAPTMEN1
SCHEMBL143786 0.84 JAK2 (0.52) PLA2G2AJAK2MEN1KMT2AALDH1A1
SCHEMBL142075 0.84 PLA2G2A (0.46) PLA2G2ACCR2JAK2KDM4EMAPT
SCHEMBL145790 0.81 CCR2 (0.46) PLA2G2ACCR2KDM4EMAPTMEN1
SCHEMBL109351 0.79 L3MBTL1 (0.41) PLA2G2ADHODHMAPTKMT2ATP53
SCHEMBL109314 0.77 CACNA1H (0.42) PLA2G2ADHODHMAPTMEN1KMT2A
SCHEMBL178706 0.76 CACNA1H (0.44) PLA2G2AJAK2KDM4EMAPTKMT2A
SCHEMBL143937 0.74 PPARG (0.44) PLA2G2AP2RX3KDM4ETP53ALDH1A1
SCHEMBL142452 0.74 JAK2 (0.58) PLA2G2AJAK2KDM4EDHODH

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8815840-B2 Carbazole and carboline kinase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2014-08-26 — — US disclosed
US-8815840-B2 Carbazole and carboline kinase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2014-08-26 — — US disclosed
EP-2370407-B1 CARBAZOLE AND CARBOLINE KINASE INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2014-06-18 — — EP disclosed
US-20120058988-A1 CARBAZOLE AND CARBOLINE KINASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY 2012-03-08 — — US disclosed
US-20120058988-A1 CARBAZOLE AND CARBOLINE KINASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY 2012-03-08 — — US disclosed
EP-2370407-A1 CARBAZOLE AND CARBOLINE KINASE INHIBITORS Bristol-Myers Squibb Company (US) 2011-10-05 — — EP disclosed
WO-2010080474-A1 CARBAZOLE AND CARBOLINE KINASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2010-07-15 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120058988-A1 CARBAZOLE AND CARBOLINE KINASE INHIBITORS JAK2, JAK1, JAK3 PLA2G2A 4509/4885P2RX3 3501/4885CCR2 524/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.